Abstracts 2017
- OP001 Whole genome sequencing and imputation in inflammatory bowel disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights
- OP002 Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C study
- OP003 Increased risk of acute arterial events in young patients with severely active inflammatory bowel disease: a nationwide French cohort study
- OP004 Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease
- OP005 The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy
- OP006 Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial
- OP007 A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis
- OP008 An innovative treatment for refractory perianal fistulas in Crohn's disease: local micro reinjection of autologous fat and adipose derived stromal vascular fraction
- OP009 Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial
- OP010 Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years
- OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study
- OP012 Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis
- OP013 Disease management and outcomes of patients with Crohn's disease at high risk of recurrence. Results from PRACTICROHN study
- OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension
- OP015 Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C TRIAL
- OP016 Potential role of bile acid receptor FXR in microscopic colitis
- OP017 Telemedicine enables a safe shift from examination room based care to personalised care for inflammatory bowel disease: a pragmatic randomised multicenter trial with myIBDcoach
- OP018 Optimal anti-TNF stop week during pregnancy depends on anti-TNF type
- OP019 Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301)
- OP020 Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's disease
- OP021 Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trial
- OP022 Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study
- OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
- OP024 Childhood-onset inflammatory bowel disease and risk of cancer – a Swedish nationwide cohort study 1964–2014
- OP025 Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice
- OP026 Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel disease
- OP027 IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in colitis-associated colorectal cancer
- OP028 Gut specific regulatory T cells – a new frontier for Crohn's disease therapy
- OP029 Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's disease
- OP030 Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation
- OP031 Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study
- OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial
- OP033 Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor
- OP034 Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
- OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease
- OP036 Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial
- OP037 Infants born to mothers with inflammatory bowel disease exhibit distinct microbiome features that persist up to 3 months of life
- OP038 Impact of ileocecal resection in Crohn's disease patients on mucosal microbiota
- P001 The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBD
- P002 Inhibition of Axl signaling by BGB324 reduces fibrogenesis in human intestinal cells and human intestinal organoids
- P004 Stimulation of CYP450-mediated ω-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease
- P005 Establishing a porcine model to translate anorectal stem cell organoid models to elucidate the aetiology of perianal Crohn's fistulae
- P006 Transcriptomic profiling of intestinal macrophages isolated from patients reveals a profound gene expression reprogramming underlying IBD pathogenesis
- P007 Oral tyrosine kinase 2 inhibitor ameliorates T cell transfer colitis
- P008 Common and different inflammatory features in inflammatory bowel disease and colon cancer
- P009 Autophagy stimulation reduces mucosal NF-κB protein levels and ameliorates murine colitis
- P010 Effects of cigarette smoke on the DSS-induced colitis model in C57Bl/6 mice
- P011 Evaluation the intestinal barrier function patients with inflammatory bowel disease
- P012 Ral activation exacerbates colonic inflammation through the impairment of intestinal barrier function in experimental murine colitis
- P013 Decreased fibrogenesis in CH25H knockout mice in a mouse model of intestinal fibrosis
- P014 Mucosal lymphocyte subsets in ulcerative colitis at diagnosis and during follow-up
- P015 Wnt10b promotes fibrosis in murine colitis
- P016 Pregnancy in IBD: direct effect of sex-hormones on epithelial barrier function
- P017 OGR1 (GPR68) expression is increased in intestinal inflammation and correlates with disease activity in patients with IBD
- P018 Complete metabonomic and microbiota profiling identifies biomarkers for anti-TNF therapy response
- P019 Anti-TNF-alpha therapy induces microbial and immunological changes in dextran sodium sulphate chronic colitis
- P020 Wnt5b could contribute to regeneration of the epithelium in inflammatory bowel disease by potentiating epithelial mesenchymal transition
- P021 Utility of therapeutic anti-TNF drug monitoring in hospitals with different degree of experience in the treatment of inflammatory bowel disease
- P022 MET deletion in MRP8+ neutrophils is protective during DDS-induced colitis via Th17 pathway
- P023 Fatigue in quiescent inflammatory bowel disease is associated with low GM-CSF levels and metabolomic alterations
- P024 Stratification of ulcerative colitis patients according to distinctive tissue cytokine profiles
- P025 Transcriptional and molecular pathways activated in mesenteric adipose tissue and intestinal mucosa of Crohn's disease patients
- P026 The role of fibrocytes in mesenteric Crohn's disease
- P027 Comparing the immunological signatures of inflammatory diseases
- P028 Oligonol attenuates dextran sulfate sodium-induced colitis and reduces flare-UP in mice by enhancing host defense mechanism
- P029 Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6
- P030 Inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory cell adhesion and recruitment to colon epithelium
- P031 Identification of alternative splicing in transcript isoforms in patients with ulcerative colitis: effects of disease duration
- P032 The pharmacological profile of TOP1288, a narrow spectrum kinase inhibitor in clinical development as an anti-inflammatory treatment for ulcerative colitis
- P033 DSS-induced colitis is attenuated in sigma-1 receptor knockout mice
- P034 Altered microbiota and host-bacterial interactions during the spontaneous development of colitis in IL-10 knockout mice
- P035 TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab
- P036 Human peripheral blood monocytes and intestinal macrophage populations activate transforming growth factor beta via expression of the integrin alpha v beta 8
- P037 MDR1-deficiency unmasks mitochondrial dysfunction as a pathogenic mechanism in IBD
- P038 Tissue differences in the pro-inflammatory activation of ER stress of patients with Crohn's disease
- P039 Suppression of phospholipase A2 of intestinal microbiota by the phospholipid-bile acid conjugate ursodeoxycholate-lysophoshatidylethanolamide ameliorates mucosal inflammation in a genetic mouse model of ulcerative colitis
- P040 Intestinal EP4 receptor is required for homeostasis of the colon in mice
- P041 C-jun n-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine
- P042 Expression of IL-38 and their antagonists in patients with inflammatory bowel disease
- P043 Ulcerative colitis is characterised by an exaggerated onset of acute inflammation with delayed resolution
- P044 Therapeutic effects of mesenchymal stem cells induced regulatory dendritic cells on chronic colitis model in mice
- P045 5-Aminosalicylates promote inflammation resolution in ulcerative colitis through generation of anti-inflammatory hydroxy fatty acids
- P046 Starch consumption is associated with serologic responses in patients with ulcerative colitis and an ileo-anal pouch
- P047 Therapeutic dosing of filgotinib (GS-6034, GLPG0634) is efficacious in the mouse DSS model of colitis
- P048 Decreased expression of aquaporins in colonic biopsies from collagenous colitis patients. A novel diarrhoeal pathomechanism?
- P049 Lewis score: a useful tool for the diagnosis but not for the definition of prognosis in suspected Crohn's disease
- P050 Centrally-determined standardization of flow cytometry methods reduces inter-laboratory variation in a prospective multicenter study
- P051 Use of digital technology to boost patient recruitment in inflammatory bowel disease clinical trials
- P052 The role of TDAG8 in intestinal inflammation
- P053 Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: a role for α4β7 in myeloid cell recruitment to the inflamed intestine
- P054 Metformin protects against intestinal barrier disruption via AMPKα1-dependent inhibition of JNK signaling pathway
- P055 Mitochondrial DNA is a damage-associated molecular pattern released during active IBD promoting TLR9-mediated inflammation
- P056 Gut microbiota characterisation in South Asian IBD patients resident in the UK
- P057 IL-6 induces NLRP3 inflammasome activation through JAK/STAT3-dependent NOX2 induction in colon epithelial cells
- P058 Comparison of Calprotectin levels in stool and rectal mucus in subjects with suspected or confirmed inflammatory bowel disease
- P059 Mucosal inflammation promotes activation of circulating Vδ2+ T-cells in Crohn's disease
- P060 Role of innate lymphoid cells in the chronic colitis under anti-il-17a therapy
- P061 Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – IBD Character
- P062 The narrow spectrum kinase inhibitor TOP1288 demonstrates potent anti-inflammatory effects in a T cell adoptive transfer colitis model through a topical mode of action
- P063 HDAC as versatile regulators of the intestinal epithelial barrier in inflammatory bowel disease
- P064 EBI2 and oxysterols in the development of intestinal lymphoid structures and colitis
- P065 Effects of gut bacteria on the intestinal immune cell composition and barrier function
- P066 Fibrostenotic phenotype of fibroblasts in Crohn's disease is dependent on tissue stiffness and reversed by LOX inhibition
- P067 Molecular profiling of early Crohn's disease reveals a prominent role for WNT5A
- P068 Evaluation of the therapeutic potential of metformin-pretreated tonsil-derived mesenchymal stem cells in a chronic colitis model
- P069 Sympathetic but not vagal intestinal innervation regulates murine dextran sodium sulphate-induced colitis
- P070 TNFα production by classical monocytes is poorly controlled by IL-10 in patients with IBD
- P071 The mesentery in Crohn's disease displays mesenchymal abnormalities
- P072 The role of the rs8005161 polymorphism on pH-sensing G protein-coupled receptor GPR65 (TDAG8) signalling in intestinal inflammation
- P073 Age dependent decrease in gut-homing CD4 lymphocytes
- P074 Decreased levels of circulating protein S (PROS1) in patients with active Crohn's disease
- P075 Calponin 2 protects against colitis associated cancer in mice through mediating inflammatory responses
- P076 IL-26 genetic polymorphisms impair cytokine response to bacterial DNA translocation and increase anti-TNF consumption in patients with Crohn's disease
- P077 Histological remission in ulcerative colitis: an analysis of two independent cohorts
- P078 Gut microbiome profiling of MMP-9 deficient mice and their wild-type littermates in a model of acute DSS-induced colitis
- P079 Association of gut microbiota with mucosal inflammation in ulcerative colitis
- P080 IL-10 induction properties of the TLR-9 agonist cobitolimod – a candidate for treatment of active ulcerative colitis in late stage of clinical development
- P081 10 years of the UK Inflammatory Bowel Disease (IBD) Audit and the journey is just beginning
- P082 An investigation of azathioprine on autophagy pathway activity
- P083 The protective role of vitamin D3 on colitis-associated colorectal cancer in a mouse model
- P084 Investigation of non-coding RNAs as molecular markers during glucocorticoid treatment in children with inflammatory bowel disease
- P085 The effect of vitamin D on macrophage function and polarization in Crohn's disease
- P086 MMP-12, a novel mediator of nociception in Crohn's disease
- P087 Increased wnt ligands expression in M2c macrophages is associated with fibrosis in Stat6 knockout mice
- P088 Evaluation of Free Vitamin D levels in IBD pediatric patients: the role of inflammation
- P089 Extracellular matrix fragments as markers of cytokine driven intestinal damage or protection; test in a novel intestinal ex vivo model
- P090 Metformin induces late Apoptosis and modulates dysbiosis in western-style diet induced colitic cancer
- P091 Usefulness of transcriptional whole blood biomarkers as a non-invasive surrogate marker of mucosal healing and endoscopic response in ulcerative colitis
- P092 Exogenous administration of IL-4-treated macrophages prevents intestinal fibrosis in Stat6 knockout mice
- P093 Dysregulation of cellular vs humoral immunity to the intestinal microbiota in inflammatory bowel disease
- P094 DNA methylation patterns in Crohn's disease mucosal-derived fibroblasts
- P095 The genetic risk in ER stress and autophagy translates into quantifiable epithelial ER stress levels in IBD patients
- P096 Combined detection variants of NUDT15 could highly predict thiopurine-induced leukopenia in Chinese patients with inflammatory bowel disease: a multi-center analysis
- P097 Th2 cytokines are potent stimulators of pro-fibrotic responses by human intestinal subepithelial myofibroblasts
- P098 Oregonin inhibits intestinal epithelial injury by modulating heme oxygenase-1
- P099 Altered intrinsic brain function in Crohn's disease
- P100 Intestinal epithelial cells under endoplasmic reticulum stress boosts serine proteolytic activity and modulates barrier function
- P101 Interleukin-13 induces polarity defects in the intestinal epithelia
- P102 Hypoxia reduces inflammation through the downregulation of NLRP3/mTOR signaling and the activation of autophagy
- P103 Evaluation of efficacy of new vectors for siRNA CYCLIN D1 and E2F1 delivery in control of cancer progression in inflammatory bowel disease
- P104 Rebamipide, sucralfate, and rifaximin have the suppressive effects on radiation-induced inflammation in the intestine of mouse
- P105 An experimental examination of appetite and disordered eating in Crohn's disease patients
- P106 Binding properties of human TLR-9 receptor to cobitolimod – a candidate for treatment of active ulcerative colitis in late stage of clinical development
- P107 Lactobacillus plantarum 06CC2 induces intestinal IL-10–producing dendritic cells to ameliorate acute experimental colitis in mice
- P108 Oleuropein decreases interleukin-17 and attenuates inflammatory damage in colonic mucosa from ulcerative colitis patients
- P109 Profiling of receptor for advanced glycation end products expression in cases of primary sclerosing cholangitis with ulcerative colitis
- P110 Characterization of human intestinal macrophage subsets in health and inflammatory bowel disease
- P111 The anti-inflammatory effect of a serine protease inhibitor in a chronic colitis transfer model is mediated by the suppression of Th1 cell differentiation
- P112 Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development
- P113 Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients
- P114 Fecal loss of infliximab is underestimated due to proteolysis
- P115 Escherichia coli Nissle 1917 modulate gut microbiota composition in ulcerative colitis patients
- P116 Escherichia coli Nissle 1917 distinctively regulates apoptosis and cell cycling of Caco-2 cells
- P117 Functional implications of microRNAs in Crohn's disease revealed by integrating microRNA and messenger RNA expression profiling
- P118 Balancing JAK/STAT-signaling with Tofacitinib in monocytes of healthy controls and IBD patients
- P119 Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn's disease: a SONIC post hoc analysis
- P120 A single-nucleotide polymorphism in the vitamin D receptor gene is associated with a B3-penetrating phenotype in Crohn's disease
- P121 Antimicrobial antibodies and inflammatory markers are present in the serum of patients with IBD years before diagnosis and can predict disease
- P122 Magnetic resonance index of activity (MaRIA) and Clermont score are two MRI indices which are highly and equally effective in detecting mucosal healing in Crohn's disease
- P123 MRI remission after therapeutic intervention is associated with more time spent in clinical corticosteroids-free remission and decreased risk of surgery in Crohn's disease
- P124 Disagreement among gastroenterologists in the endoscopic evaluation using the Mayo endoscopic score and the Rutgeerts postoperative score
- P125 Rapid increase in pan-treatment refractory Crohn's disease after transition to adult services: a regional cohort study
- P126 Experience of 3D modelling in perianal fistula disease and survey of international surgical interest
- P127 An assessment of a pancolonic adaptation of the ulcerative colitis endoscopic index of severity in comparison to clinical and biochemical markers of disease activity in paediatric ulcerative colitis
- P128 Diagnostic accuracy of faecal calprotectin in Crohn's disease – Does disease location matter?
- P129 Persistent intestinal inflammation leads to surgical intervention in Crohn's patients: a nested case-control study
- P130 Ingestion of 100ml and 300ml blood mimicking upper gi bleeding leads to significant calprotectin elevation in healthy volunteers – results from the “Vampire study”
- P131 Fecal micro-RNAs indicate disease activity in ulcerative colitis
- P132 Cooperation to improve quality of IPAA surgery in IBD: south Netherlands experience
- P133 A novel candidate pathway for development of neoplasms with serrated morphology in patients with ulcerative colitis
- P134 Point of care ultrasound accurately distinguishes inflammatory from non inflammatory disease in patients presenting with abdominal pain and diarrhea
- P135 The early course of Crohn's disease: prognostic and treatment modalities during the first year of disease
- P136 Sporadic adenomas in IBD patients over 50 years old and average risk population – Is there a difference?
- P137 Ulcerative colitis in the elderly – Different disease course?
- P138 Does depression at IBD diagnosis impact on disease outcomes in Crohn's?
- P139 Articular manifestations in inflammatory bowel disease – results from Northeastern Romania
- P140 Use of vedolizumab in a transplanted liver patient: a case report of the first experience in a liver transplant referral center in Argentina
- P141 Characteristics and outcomes of acute colitis presenting via the emergency department in an Irish academic medical centre
- P142 Postoperative course of laparoscopic subtotal colectomy is not affected by preoperative medical treatment in patients with acute colitis complicating inflammatory bowel disease
- P143 From biopsies to fecal samples: challenging Faecalibacterium prausnitzii and related phylogroups as potential biomarkers for IBD
- P144 Protozoa and bacterial infections are relevant for clinical outcomes in ulcerative colitis: a study from Latin American country
- P145 Measuring access and quality of care indicators in inflammatory bowel disease in a tertiary referral center
- P146 Primary intestinal Epstein-Barr virus-associated NK/T-Cell lymphoproliferative disorder: a disease mimicking IBD
- P147 Metabolomics discriminate children with Crohn's disease from ulcerative colitis and from healthy controls – preliminary study
- P148 Fecal calprotectin as a noninvasive indicator for ulcerative colitis disease activity in the Korean cohort
- P149 Urban life is an independent risk factor for psychological symptoms of the Chinese patients with Crohn's disease
- P150 Pregnancy complications and outcomes in patients with inflammatory bowel disease
- P151 Spinal disorders in IBD patients 20 years after diagnosis. Results from the IBSEN study
- P152 Reconsidering the prognostic value of traditional serologic antibodies in Crohn's disease – immunoglobulin classes to take the centre stage
- P153 Role of 3D endoanal ultrasound in perianal fistulising Crohns's disease. Preliminary results
- P154 Complete sequence-based NUDT15 and TPMT variants for predicting thiopurine-induced leukopenia in patients with Crohn's disease
- P155 A retrospective analysis of Clostridium difficile infection in patients with ulcerative colitis
- P156 Microbiota diversity at time of surgery predict endoscopic recurrence in Crohn's disease: results of a prospective study of the REMIND group
- P157 Fecal calprotectin correlates to endoscopic and histologic remission in ulcerative colitis: a prospective study
- P158 Pouchitis in paediatric ulcerative colitis: a multicentre longitudinal cohort study from the Porto IBD working group of ESPGHAN
- P159 Real-time endoscopic-guided measurement of rectal mucosal admittance: a novel and safety method for prediction of relapse in ulcerative colitis
- P160 Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound for evaluation of small bowel Crohn's disease: a systematic review and meta-analysis
- P161 Crohn's disease risk prediction model appropriately stratifies patients' risk for developing disease related complications
- P162 Early onset of disease and higher risk for colorectal dysplasia in IBD patients with coincidental primary sclerosing cholangitis – evidence from a large cohort study
- P163 Performance of ASAS criteria for inflammatory back pain in patients with inflammatory bowel disease
- P164 FOX04 gene expression in colonic mucosa is a potential marker associated with histological remission in patients with ulcerative colitis
- P165 Impact of double balloon endoscopy on management of small bowel Crohn's disease
- P166 Decreased expression of elafin in peripheral blood and intestinal mucosa in inflammatory bowel disease
- P167 Diagnostic accuracy of neutrophil-lymphocyte ratio in suspected paediatric inflammatory bowel disease
- P168 Validation of the red flags index for early referral of patients with symptoms and signs suggestive of Crohn's disease
- P169 Usability of a home-based test for the measurement of fecal calprotectin in IBD patients
- P170 Integrated psychological care in outpatients with inflammatory bowel disease
- P171 Reliable assessment of ultrasound parameters during transabdominal ultrasonography in inflammatory bowel disease
- P173 Risk stratification of patients with Crohn's disease: a retrospective analysis of clinical decision-making and its impact on long-term outcome
- P174 Optimal time interval required for correlation between fecal calprotectin test and endoscopy
- P175 A novel small-caliber deep enteroscope can overcome technical difficulty of insertion in patients with Crohn's disease
- P176 Correlation of biomarkers to PET/MRI and endoscopy in patients with Crohn's disease with special focus on small bowel involvement
- P177 Histological features in paired ileal resections in Crohn's disease patients
- P178 Validation of the clinical utility of IFI16-based markers in IBD
- P179 Diagnostic performance of low haemoglobin density (LDH%) for detecting iron deficiency in IBD patients
- P180 Investing in workability of patients with IBD: results of a pilot project Activ84worK (Activate for worK)
- P181 Home smart-phone based measurement of fecal calprotectin by IBD patients: correlation with laboratory assay and applicability as patient-friendly monitoring tool
- P182 Assessing the effect of ethnicity on urinary metabolic profiles in inflammatory bowel disease
- P183 Psychosocial impact of inflammatory bowel disease and its practice management as perceived by patients and physicians in Spain. The ENMENTE Project
- P184 Photoprotective behaviours in inflammatory bowel disease patients on azathioprine and TNF-α inhibitors
- P185 Validity of contrast enhanced ultrasonography and dynamic contrast enhanced MR enterography in the assessment of Crohn's disease
- P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease
- P187 Differential distribution of Epstein-Barr virus and Cytomegalovirus in colonic mucosa in patients with active ulcerative colitis
- P188 Crohn's disease of the terminal Ileum: PET-MRE results correlate well with biomarkers
- P189 Serum neutrophil gelatinase-associated lipocalin correlates with Mayo Clinic score in ulcerative colitis but fails to predict activity in Crohn's disease
- P190 Comparison of two endoscopic scores of inflammatory activity in small-bowel Crohn's disease and its correlation with clinical activity and biomarkers
- P191 The robotic surgery in the treatment of Crohn's disease: our experience
- P192 Heartburn in Crohn's disease is associated with increased disease activity, poor sleep quality and prior ileocecectomy
- P193 Faecal calprotectin differentially predicts postoperative endoscopic recurrence in Crohn's disease according to therapy. A prospective multicenter study
- P194 Anti-TNFα treatment following surgical resection for Crohn's disease is effective despite previous pharmacodynamic failure
- P195 The utility of fecal microRNAs in the diagnosis of inflammatory bowel disease
- P196 Patients with ulcerative colitis (UC) and concomitant primary sclerosing cholangitis (PSC) have more subclinical endoscopic and histologic disease activity in the right colon compared to UC patients without PSC
- P197 Improved maternal and neonatal outcomes in a clinic dedicated to pregnant patients with inflammatory bowel disease
- P198 Dipeptidyl peptidase 4: a strong predictive marker of disease activity and treatment escalation in inflammatory bowel diseases
- P199 PET/MR for evaluating subclinical inflammation of ulcerative colitis in remission
- P200 Faecal calprotectin as a marker of relapse in inflammatory bowel disease – its place in the management algorithm and cost effectiveness in Poland
- P201 A faecal bacterial markers correlates with Calprotectin for IBD activity monitoring?
- P202 Diagnosis of inflammatory bowel disease in asymptomatic subjects: disease characteristics, natural history and treatment requirements
- P203 Factors associated with restless legs syndrome in patients with ulcerative colitis: a study in a tertiary care center in Romania
- P204 Lipid profile in inflammatory bowel disease under maintenance wih anti-TNF: a prospective longitudinal cohort study
- P205 A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial
- P206 Celiac disease and inflammatory bowel disease, a rare association
- P207 Prevalence and characteristics of Romanian patients with upper GI tract involvement in Crohn's disease
- P208 Long term follow up of lymphocytic colitis patients
- P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study
- P210 The associations of optimism, social support, and coping strategies with health-related quality of life in a cohort of patients after proctocolectomy with ileal Pouch-anal anastomosis
- P211 Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 multicentre fistula cohorts
- P212 Location and Kudo pit pattern reflect neoplastic histology of lesions detected at surveillance colonoscopy in inflammatory bowel disease
- P213 Agreement between Crohn's disease endoscopy severity scores derived from live local, delayed local video-recorded and central readings
- P214 What is the diagnostic accuracy of faecal calprotectin regarding endoscopic relapse in Crohn's disease patients following ileocecal resection? A tertiary single center experience
- P215 Clinical features of chronic enteropathy associated with SLCO2A1 gene (CEAS)
- P216 Mesenteric disease is directly related to mucosal disease in Crohn's disease
- P217 The relationship between thiopurine use during pregnancy and anemia in the offspring during the first year of life
- P218 Venous thromboembolism in a Finnish IBD cohort
- P219 Inflammatory bowel disease in children is a challenging diagnosis when overlaps with coeliac disease
- P220 Current practices in Ileal pouch surveillance for ulcerative colitis patients in Three London IBD referral centres
- P221 Natural history of perianal Crohn's disease in patients with elderly-onset disease: a population-based study
- P222 Sequential MRI volume measurements of perianal fistulae in Crohn's disease
- P223 C-reactive protein improvement after vedolizumab induction phase is associated with remission after 6 months of treatment in ulcerative colitis patients
- P224 Virtual chromoendoscopy with i-Scan as alternative to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease
- P225 Clinical characteristics of patients who have inflammatory bowel disease associated with hyperamylasemia and pancreatitis
- P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis
- P227 Outcomes of anti-TNF versus Vedolizumab therapy for ulcerative colitis: the Leeds experience
- P228 Prevalence and risk factor of CMV infection among hospitalized patients with ulcerative colitis
- P229 The modified postoperative endoscopic recurrence score for Crohn's disease: Does it really make a difference in predicting clinical recurrence?
- P230 Methotrexate in the treatment of Crohn's disease: a Portuguese real-life single center experience
- P231 Backgrounds and D-dimer on admission are useful factors for predicting venous thromboembolic complications in hospitalized patients with inflammatory bowel disease
- P232 Atherosclerosis in ulcerative colitis
- P233 Diagnostic delay in a large cohort of patients with inflammatory bowel disease – results of a multicenter study of the Austrian IBD Study Group (ATISG)
- P234 Recent trends in microscopic colitis: demographics, clinical features and outcomes in a Portuguese cohort
- P235 Endoscopic, clinical, and surgical recurrence of Crohn's disease: In which direction are we going?
- P236 Fecal calprotectin as suitable biomarker in evaluation of histological disease activity
- P237 Hair mineral and trace element contents as reliable markers of nutritional status compared to serum levels in children with inflammatory bowel disease
- P238 Mental health issues and healthcare utilisation in outpatients with inflammatory bowel disease
- P239 A novel user friendly model to identify key predictors of corticosteroid utilization in newly diagnosed patients with ulcerative colitis
- P240 Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study
- P241 Defining patient-centered outcomes for IBD – an international, cross-disciplinary consensus
- P242 Phenotypic characterisation of elderly – onset inflammatory bowel disease – IBD at the extremes
- P243 Complications of newly diagnosed Crohn's disease can be predicted by mathematical modeling of serologic responses
- P244 Diffusion-weighted MRI enables to accurately grade inflammatory activity in patients of ileocolonic Crohn's disease: results from an observational study
- P245 A systematic review of outcomes reported in studies on fistulising perianal Crohn's disease
- P246 Risk factors associated with low ovarian reserve in young women of reproductive age with Crohn's disease
- P247 Fungal infections in children with inflammatory bowel disease
- P248 The new infliximab point-of-care quantitative test can equally be used for therapeutic drug monitoring of biosimilars of infliximab
- P249 Usefulness of abdominal ultrasonography for patency assessment using the patency capsule
- P250 DUBLIN (Degree of Ulcerative Colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in ulcerative colitis
- P251 The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study
- P252 Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients Crohn's disease
- P253 Effects of time on urinary metabolic signatures in inflammatory bowel disease
- P254 Relationship between severe endoscopic lesions and plasmatic and fecal infliximab levels in acute severe ulcerative colitis: a case control study
- P255 Predictors of negative C-reactive protein in active Crohn's disease
- P256 Correlation of fecal calprotectin levels with endoscopic severity evaluated with balloon-assisted endoscopy in patients with Crohn's disease
- P257 Evaluation of serum ICAM-1 and VCAM-1 as biomarkers for disease progression in Crohn's disease
- P258 Disease course and operative risk after diagnosis of ileal penetrating Crohn's disease: a cohort study
- P259 The clinical course of ulcerative colitis after orthotopic liver transplantation in context of HLA-DR mismatch
- P260 Endoscopic surveillance in ulcerative colitis: an Algerian prospective study
- P261 Grading post-operative recurrence in Crohn's disease: a comparison between MRE and ileocolonoscopy
- P262 Evaluation of zinc as a biomarker of a complicated course in paediatric Crohn's disease
- P263 De-novo inflammatory bowel disease after bariatric surgery: a novel association
- P264 Relation of inflamed resection margins to postoperative complications in Crohn's disease
- P265 Comparison of two faecal calprotectin assays in monitoring children with inflammatory bowel disease
- P266 Risk factors for colorectal neoplasia in ulcerative colitis
- P267 Candidate serum markers in newly diagnosed Crohn's disease patients
- P268 Fecal calprotectin correlates more highly with endoscopic disease activity than symptom-based disease activity markers in paediatric PSC-IBD
- P269 Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's disease: an NIDDK IBD Genetics Consortium prospective study
- P270 Correlation between endoscopic and histological activity in ulcerative colitis using validated indices
- P271 Complications of primary sclerosing cholangitis in patients with ulcerative colitis and normal liver function tests: a prospective magnetic resonance cholangiographic study with long-term follow-up
- P272 Faecal calprotectin and magnetic resonance imaging are highly accurate to detect endoscopic postoperative recurrence in Crohn's disease
- P273 Prediction of treatment response in Crohn's disease patients using contrast enhanced ultrasound: a pilot study
- P274 Assessing the individual risk of acute severe colitis at diagnosis in a South Asian population
- P275 Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO score (the Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis
- P276 A snap-shot review of small bowel capsule endoscopy in the setting of inflammatory bowel disease
- P277 Comparative accuracy of US versus MRI and colonoscopy in assessing disease activity and complications and influencing the decision-making process in Crohn's disease
- P278 Short and long-term surgical outcomes and pouch function following proctocolectomy and pouch formation in paediatric ulcerative colitis: a multicentre-retrospective cohort study from the Porto IBD working group of ESPGHAN
- P279 Children born to mothers with inflammatory bowel disease – Is there any risk for newborns' complication and development during the childhood?
- P280 Therapeutic drug monitoring of infliximab and adalimumab for detection of patients at risk of loss of response in inflammatory bowel disease
- P281 Factors at diagnosis associated with disabling disease course in Crohn's disease
- P282 Does colonoscopy alter the post-procedural fecal calprotectin results in Crohn's disease patients with ileocecal resection?
- P283 Quantum blue® adalimumab: development of the first point of care rapid test for therapeutic drug monitoring of serum adalimumab levels
- P284 Ulcerative colitis – presentation during pregnancy or puerperium
- P285 Usefulness of a multidisciplinary approach combining both rheumatology and gastroenterology for the assessment and treatment of inflammatory bowel disease patients
- P286 Evaluation of fecal S100A12 in patients with inflammatory bowel disease
- P287 Lipid peroxidation levels and antioxidant status in serum, plasma and saliva of patients with active and inactive Crohn's disease
- P288 Treating beyond symptoms in inflammatory bowel disease (IBD): the Kent IBD Nurse Experience with the Steroid assessment tool
- P289 Outcome of endoscopic ally resected dysplasic lesions in ulcerative colitis
- P290 Evaluation of patients with retained patency capsule
- P291 Proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCA) would be a predictive biomarker for the clinical course of ulcerative colitis
- P292 Perianal disease: far beyond a simple feature of Crohn's disease
- P293 Histological risk factors to predict clinical relapse in ulcerative colitis in mucosal healing
- P294 Iron-deficiency without anemia in Crohn's disease: what are the predictive factors of recovery?
- P295 Absence of mucosal healing in patients undergoing assessment of mucosal healing with a normal PUCAI score in pediatric ulcerative colitis
- P296 Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration of Lemann Index score
- P297 Fecal calprotectin accurately predicts symptomatic relapse in children and adolescents with inflammatory bowel disease in clinical remission
- P298 Comparison between clinical and patient-reported symptoms among Crohn's disease and ulcerative colitis patients
- P299 Identification of a prognostic biomarker able to predict ulcerative colitis patients that will not respond to standard therapy
- P300 Illness perceptions and coping with health-related quality of life in patients with inflammatory bowel disease
- P301 Non-familial small bowel carcinomas in Crohn's disease: clinico-pathological, molecular and prognostic features
- P302 Cytomegalovirus infection in pediatric acute severe ulcerative colitis – a multicenter case-controlled study from the Pediatric IBD Porto group of ESPGHAN
- P303 Gastrointestinal infectious agents detected by Biofire FilmArray GI PCR panel stool testing in active inflammatory bowel disease are common and associated with a more benign course of IBD
- P304 Zinc levels, interplay with ATG16L1 and disease outcome in Crohn's disease patients in the Swiss IBD cohort study
- P305 Indirect comparison of two novel biologics for the treatment of Crohn's disease : network-meta analysis of ustekinumab vs vedolizumab
- P306 What is the impact of perianal disease on anorectal function and quality of life of IBD patients? A prospective observational study
- P307 Fecal Lactoferrin levels are stable during pregnancy
- P308 Safety of the given patency capsule in patients with Crohn's disease or suspected Crohn's disease
- P309 Impact of rapid access MR on clinical decision making and patient management in Crohn's disease in a tertiary referral center
- P310 Development of a new clinico-biological score associated with disease activity in patients with inflammatory bowel disease treated with thiopurine
- P311 Microscopic inflammation and myenteric plexitis at the margin of resection do not predict endoscopic recurrence in patients with Crohn's disease after ileocolic resection
- P312 Trabecular bone score in patients with inflammatory bowel diseases
- P313 Glycan antibodies and pANCA in newly diagnosed inflammatory bowel disease patients at presentation and during follow-up
- P314 Management of perianal disease in patients with Crohn's disease
- P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
- P316 New approaches for IBD management based on text mining of digitalised medical reports and latent class modelling
- P317 Postoperative complications, outcome, quality of life and self-image after ileal pouch-anal anastomosis in patients operated due to acute, severe or chronic, therapy refractory ulcerative colitis
- P318 Accuracy of magnetic resonance enterography for extraluminal complications of Crohn's disease
- P319 Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin
- P320 Utility of a semi-quantitative rapid test in diagnosis of ulcerative colitis
- P321 Activity graph patterns recorded using a mobile monitoring system are associated with clinical outcomes of patients with Crohn's disease
- P322 A change in ΔMCV predicts mucosal healing in patients with Crohn's disease under combination therapy
- P323 Fatty liver assessment in inflammatory bowel disease patients using controlled attenuation parameter
- P324 Evaluation of ability to predict mucosal healing by quantitative fecal immunochemical test in ulcerative colitis
- P325 Combination therapy with adalimumab and immunomodulators decreases incidence of intestinal resection in Crohn's disease patients previously treated with infliximab: a large, multicentre cohort study
- P326 Efficacy of vedolizumab on patient-reported outcomes in ulcerative colitis patients: results from a prospective German observational study
- P327 Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study
- P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey
- P329 Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
- P330 Discontinuation of corticosteroids among ulcerative colitis patients treated with vedolizumab in the United States
- P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
- P332 Treat to target in Crohn's disease: ultrasonographic response is associated with better outcomes
- P333 Changing patterns of biological therapy use with the introduction of biosimilars in inflammatory bowel disease
- P334 Medication adherence in diverse inner city pediatric patients with inflammatory bowel disease and comparison to physician perception of adherence
- P335 Prevalence and risk factors for non alcoholic fatty liver disease in inflammatory bowel disease
- P336 Safety of anti-TNF treatment in older IBD patients: a systematic review and meta-analysis
- P337 Efficacy of intravenous cyclosporine in fulminant steroid-refractory ulcerative colitis with massive bleeding: a retrospective, observational study
- P338 Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal
- P339 MadCAM1 expression in intestinal lamina propria endothelium varies among inflammatory bowel disease patients
- P340 Prevalence and long-term effect of antiplatelet use in inflammatory bowel disease
- P341 Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice
- P342 Maladaptive coping, self-efficacy and patient reported outcomes in inflammatory bowel disease
- P343 Female gender, somatization and presence of IBS-type symptoms predicts Dyspareunia in patients with IBD
- P344 Vitamin D-Induced alterations in Cytokine levels lower the risk of clinical relapse in ulcerative colitis
- P345 Inconsistency between electronic data of patient's adherence and self reported adherence score
- P346 Dietary practices and beliefs among parents of children with inflammatory bowel disease: preliminary results
- P347 Evaluation of step up therapy in patients with early ulcerative colitis: a prospective cohort study
- P348 Persistent hyperCKemia during infliximab therapy in patients with inflammatory bowel disease
- P349 The therapies influencing postoperative surgical recurrence in Crohn's disease
- P350 Induction of antiphospholipid antibodies in patients with inflammatory bowel disease treated with anti-TNFα agents
- P351 Do self-selected “Non-Transitioned” referrals from peadiatric services have lower treatment requirements?
- P352 Assessment of the use of therapeutic drug monitoring of Adalimumab during maintenance therapy in children with inflammatory bowel disease
- P353 Long-term safety of adalimumab in patients with Crohn's disease: final data from PYRAMID registry
- P354 The effect of value based health care delivery for inflammatory bowel diseases on outcomes of patients
- P355 A structured care pathway improves quality of care for acute severe ulcerative colitis
- P356 Treatment with anakinra induces T cell production of IL22 and GI mucosal healing in an IL-10RA mutation patient
- P357 A multi-institutional report of postoperative outcomes in Vedolizumab-Treated patients undergoing major abdominal operations for inflammatory bowel disease
- P358 Efficacy of golimumab for the treatment of ulcerative colitis patients in clinical practice: a retrospective cohort study
- P359 Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries
- P360 Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patients
- P361 Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remission
- P362 Magnetic resonance healing predicts long-term outcomes in patients with Crohn's disease
- P363 The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study
- P364 A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel disease
- P365 Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
- P366 The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease – a multicenter European real world experience
- P367 The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-making
- P368 Treatment of inflammatory bowel disease in the elderly
- P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers
- P370 A randomised controlled trial of acceptance and commitment therapy for the treatment of stress in inflammatory bowel disease
- P371 Healthcare maintenance in inflammatory bowel disease patients: need for a top down approach
- P372 The long term course of patients undergoing ileal pouch-anal anastomosis for ulcerative colitis
- P373 Real-file prospective experience with adalimumab in inducing remission in ulcerative colitis in Italian primary inflammatory bowel diseases centres
- P374 Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease
- P375 Intraoperative endoscopy is safe and helps to determine the resection extent in Crohn's disease
- P376 Assessment of nutritional status and food related experience of adult inflammatory bowel disease inpatients
- P377 Evaluation of the pharmacokinetic profiles of SB5 and reference adalimumab
- P378 Renal AA amyloidosis associated with Crohn's disease
- P379 Is febuxostat the solution for patients who develop side effects to low dose azathioprine and allopurinol co-therapy?
- P380 Assessment of the awareness and education of vaccination in our IBD cohort: an observational study
- P381 Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease
- P382 A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis
- P383 Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada
- P384 Long-term outcome and endoscopic healing rates following long modified side-to-side strictureplasties
- P385 Assessment of long-term outcomes of patients with ulcerative colitis and mucosal healing under different therapies: Is all mucosal healing the same?
- P386 A target 6-thioguanine nucleotide ≥125 is associated with a higher rate and longer durability of response in infliximab–thiopurine combination therapy: a retrospective study in Crohn's disease patients
- P387 The addition of an immunosuppressant is an effective optimization strategy after loss of response to anti-TNF-alpha monotherapy in patients with inflammatory bowel disease: a two-year experience
- P388 Risk of relapse in ulcerative colitis patients in clinical remission with combination therapy (anti-TNF and azathioprine) after immunomodulator discontinuation
- P389 Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn's disease after ileal resection
- P390 Open-label study to evaluate the pharmacokinetics of fidaxomicin in inflammatory bowel disease patients with Clostridium difficile infection (the PROFILE study): pharmacokinetics analysis
- P391 Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United Kingdom
- P392 Comparison of dietary nutrient and food additive intake between patients with moderately active ulcerative colitis, healthy stool donors and the general Australian population
- P393 Evaluation of pharmacokinetic profiles of SB2 as a biosimilar of reference infliximab
- P394 Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease
- P395 Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)
- P396 Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitis
- P397 Approach and management of psychological aspects of inflammatory bowel disease described by patients and physicians in Spain. The ENMENTE Project
- P398 An objective measure of response to treatment for patients with Crohn's perianal fistulas on anti-TNF treatment
- P399 Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients
- P400 Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection
- P401 Anti-TNF treatments in Crohn's disease and improvement in work productivity and quality of life: an observational study from Turkey
- P402 Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapse
- P403 Golimumab therapy for ulcerative colitis – an Irish multicentre experience
- P404 Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD study
- P405 Toxicity of thiopurines in patients with inflammatory bowel disease: inventory and predictive factors
- P406 Clinical correlations of infliximab trough levels and antibodies to infliximab in Korean patients with Crohn's disease
- P407 Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre
- P408 Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in Norway
- P409 Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study
- P410 Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSC
- P411 Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
- P412 The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy
- P413 Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's disease
- P414 Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
- P415 Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011
- P416 Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience
- P417 Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's disease treated with methotrexate
- P418 Pharmacodynamic biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trial
- P419 Concentrations of anti-TNF agents in non-inflamed intestinal tissue are associated with the long-term outcome of patients with Crohn's disease
- P420 Anti-TNF for post-operative prevention in Crohn's disease: the detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrence
- P421 Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe ulcerative colitis: a systematic review and network meta-analysis
- P422 Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assay
- P423 Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trial
- P424 Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy
- P425 Biosimilar infliximab in real-life Crohn's disease treatment in anti-TNF-alpha naïve and non-naïve patients in comparison to biologic originator: a comparative observational cohort study
- P426 Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patients
- P427 Neutrophil-to-lymphocyte ration in ulcerative colitis predicts sustained response to infliximab
- P428 Optimizing thiopurines in Crohn's disease: low dose and low 6-TGN level are effective for maintenance of remission in Asian population
- P429 Mucosal healing after 3 months of conventional IBD treatment: real life data
- P430 EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experience
- P431 Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab dose
- P432 Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort study
- P433 Postsurgical recurrence in Crohn's disease. Multicenter study in the region of Murcia, Spain of GEMEII group
- P434 Joint Inflammatory Bowel Disease–Obstetric clinics: outcomes in 95 pregnancies at a tertiary centre over a 3-year period
- P435 The mean corpuscular volume flow – prognostic value for inflammatory bowel disease under thiopurine treatment
- P436 Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice
- P437 Autologous hematopoietic stem cell transplantation for refractory Crohn's disease: predictive factors of relapse
- P438 Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study
- P439 Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease
- P440 Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter study
- P441 Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study
- P442 Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
- P443 Systematic review of internet decision making resources for patients considering surgery for ulcerative colitis
- P444 Does one size truly fit all? Co-prescription of allopurinol and thiopurine therapy results in variation of TGNs outside the therapeutic range in more than half of patients
- P445 Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn's disease undergoing right hemicolectomy with ileocolonic anastomosis
- P446 Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54
- P447 Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease
- P448 Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
- P449 Patient support program for adalimumab-treated patients with Crohn's disease in Brazil: impact on patients' adherence and persistence
- P450 Reliability assessment of endoscopic scoring tools using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network
- P451 Compound IBD patient profiles are related to specific information needs – an Israeli national survey
- P452 Silent anaemia predicts treatment change in patients with Crohn's disease in clinical remission
- P453 Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease
- P454 Can calcineurin inhibitors induce a durable remission that is maintained with vedolizumab in IBD?
- P455 Clinical features of tuberculosis infection in inflammatory bowel disease patients on anti-TNF therapy
- P456 Comparative analysis of oral versus intravenous iron in patients with inflammatory bowel disease and iron deficiency/anaemia – impact on hospitalisation in Germany
- P457 Rapid faecal calprotectin test and symptom index for monitoring the disease activity in colonic IBD
- P458 Sleep problems in inflammatory bowel disease; When bed becomes a battleground
- P459 Obesity in patients with an ileoanal pouch due to ulcerative colitis is not associated with an increased risk for pouchitis
- P460 Early use of therapeutic drug monitoring to individualize infliximab therapy in paediatric IBD: a multicentre prospective COHORT study
- P461 Comparison of efficacy of different oral 5-aminosalicylic acid doses for maintenance of remission in ulcerative colitis: a systematic review and meta-analysis
- P462 Long-term outcomes of anti-TNF therapy discontinuation in patients with penetrating Crohn's disease
- P463 Recurrence of Crohn's disease after the first surgical intervention
- P464 Recurrence of ulcerative colitis during pregnancy in patients who became pregnant during remission
- P465 Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease
- P466 Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis
- P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
- P468 Etrolizumab treatment improves histological activity as assessed by the Robarts histopathology index
- P469 Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjects
- P470 Comparative effectiveness analysis of flares, hospitalisations, and corticosteroid use among biologic naïve patients with inflammatory bowel disease within 12 months of initiation of vedolizumab or infliximab
- P471 Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experience
- P472 Original and biosimilar infliximab: Are they two faces of the same coin? The experience from a pioneer European center
- P473 How to monitor the withdrawal of maintenance treatment with azathioprine in IBD patients with deep remission: results from a prospective study on multiple non invasive tests
- P474 An enzyme-linked immunosorbent assay for therapeutic drug monitoring of vedolizumab
- P475 Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study
- P476 Sigmoidostomy or Hartman's procedure during laparoscopic subtotal colectomy for acute colitis complicating inflammatory bowel disease? A comparative study in 129 consecutive patients
- P478 The current place of probiotics in treatment of pouchitis: systematic review
- P479 Shifting the shunters in a paediatric inflammatory bowel disease population: thiopurine dose splitting versus allopurinol and thiopurine co-therapy
- P480 Characteristics of drug-induced lupus 2° to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF
- P481 Serum levels of infliximab associate with early mucosal healing in Crohn's disease: different “therapeutic window” between post-induction and maintenance treatment
- P482 Early anti-TNF/immunomodulator therapy is associated with better clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors
- P483 Relapse after discontinuation of the maintenance drug in patients with Ulcerative proctosigmoiditis: preliminary result of a prospective randomized trial
- P484 Dietary therapy using the Crohn's disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy
- P485 Dosing infliximab in Crohn's disease: Is adjustment for body size justified?
- P486 Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany
- P487 Effectiveness and safety of CT-P13 under routine care in paediatric patients with inflammatory bowel disease
- P488 Does Statin use reduce the risk of J-pouch related complications in patients with inflammatory bowel disease?
- P489 Double-dose infliximab therapy in Crohn's disease: appropriate time to evaluate the efficacy, long-term efficacy and safety
- P490 A pilot study of the electronic patient portal “Patient Knows Best” for monitoring biologic therapy in inflammatory bowel disease
- P491 Comparison of the durability of response to subcutaneous anti-TNF therapy between ulcerative colitis and Crohn's disease
- P492 Cumulative safety signal review confirmed the established safety profile of Asacol™† (mesalazine)
- P493 Efficacy of anti-TNF for internal fistula in Crohn's disease – results from a retrospective multicenter cohort study
- P494 Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula
- P495 Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival
- P496 Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's disease
- P497 Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologics
- P498 Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in ulcerative colitis
- P499 Sexual dysfunction is frequent among inflammatory bowel disease patients: results of a prospective study
- P500 Effectiveness and safety in Crohn's disease patients who were treated with CT-P13
- P501 Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)
- P502 Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment
- P503 Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice
- P504 Differences between paediatric and adult inflammatory bowel disease presentation – analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy – Satimos study
- P505 Efficacy of MMX-mesalamine monotherapy for maintenance of remission in ulcerative colitis patients after mucosal healing
- P506 Psychological factors and quality of life in inflammatory bowel diseases patients: the Psycho study
- P507 Nutrition status in pre-surgical Crohn's disease, active Crohn's disease, Crohn's disease in remission and ulcerative colitis in remission: a cross-sectional study
- P508 Association between clinical outcome and post induction CT-P13 trough levels at week 14, in patients with inflammatory bowel disease. Preliminary results in an observational multicentric study
- P509 IBD cancer and serious infections in Europe (I-CARE): a European prospective observational study
- P510 Assessment of study group – patients with inflammatory bowel disease, treated with monoclonal anti-TNF alpha: a multicenter, prospective cohort observational study, Satimos – preliminary report in pediatric population
- P511 Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)
- P512 Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitis
- P513 Managing IBD patients on adalimumab based on trough levels and antibodies
- P514 Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data
- P515 Evaluation of treatment persistence of vedolizumab among Finnish inflammatory bowel disease patients in real-life clinical practice (FINVEDO)
- P516 Adrenal suppression in inflammatory bowel disease patients treated with glucocorticoids: a systematic review
- P517 Features of cytomegalovirus infection in inflammatory bowel disease
- P518 Remission induction in corticosteroid naïve children and adolescents with ulcerative colitis by adsorptive leucocytapheresis as monotherapy or in combination with low dose prednisolone after failure of first-line medications
- P519 Anti-tumour necrosis-alpha therapy during pregnancy in patients with inflammatory bowel disease: safety in women and children
- P520 Perspective and self-efficacy of adolescents with inflammatory bowel disease post transition to adult care
- P521 A prospective cohort study to assess the relevance of Vedolizumab drug level monitoring in IBD patients
- P522 A multicenter study to validate Magnetic Resonance Enterography against histological assessments of stenotic disease in patients with Crohn's disease
- P523 Association between pharmacokinetics of adalimumab and disease outcome in Japanese patients with biologics naïve Crohn's disease: a subanalysis of DIAMOND trial
- P524 Long-term outcomes after restorative proctocolectomy and ileal pouch-anal anastomosis in children compared to adults
- P525 Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of “real world data” from the UK
- P526 A prospective 52-week mucosal healing and deep remission assessment of small bowel and colonic Crohn's disease as detected by colon capsule endoscopy
- P527 Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy
- P528 Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era
- P529 Impact of stress in inflammatory bowel disease. Effect of a group psychological intervention program
- P530 Azathioprine in the maintenance of steroid-free remission in inflammatory bowel disease patients: efficacy and safety in five years of follow-up
- P531 Discontinuation of corticosteroids among Crohn's disease patients treated with vedolizumab in the United States
- P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up
- P533 Anaemia and iron deficiency in gastroenterology: a Scandinavian prospective, observational study of iron isomaltoside in clinical practice
- P534 Illness perception in IBD patients: a prospective study
- P535 Outcomes of endoscopic resections of large non-polypoid lesions inflammatory bowel disease: a single United Kingdom centre experience
- P536 Combination therapy of bone marrow mesenchymal stromal cells and azathioprine not affect the clinical course luminal Crohn's disease
- P537 Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?
- P538 Can enteral polymeric diet change the post-surgical outcome in Crohn's disease patients? A pilot study
- P539 Does a change in therapeutic approach modify outcome in IBD patients? A comparison between two cohorts 2004–2007 and 2010–2013
- P540 Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
- P541 Intestinal failure: a rare but significant outcome of restorative proctocolectomy
- P542 Long-term outcomes after switching from originator infliximab to biosimilar in paediatric-onset inflammatory bowel disease patients: a single centre prospective observational study
- P543 Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT study
- P544 Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course
- P545 Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary results
- P546 Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?
- P547 Is there an association between bariatric surgery and Crohn's disease?
- P548 Hepatitis B virus reactivation in hepatitis B virus infected patients with inflammatory bowel disease receiving anti-tumor necrosis factor-alpha therapy
- P549 Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease
- P550 Clinical features of demyelination following anti-TNFα therapy
- P551 Smooth Seton® for perianal fistulas: a knot-less solution
- P552 An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medication
- P553 Long-term outcomes of seton drainage for perianal fistulizing Crohn's disease
- P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial
- P555 Systematic review of interventions for chronic abdominal pain management in inflammatory bowel disease
- P556 Female Crohn's disease patients and ulcerative colitis patients on biologic therapy are most disabled
- P557 Utility of “trough levels” adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic model
- P558 The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis
- P559 Treatment goals in IBD: a perspective from patients and their partners
- P560 Trough levels at induction: impact on long term response when re-initiating infliximab
- P561 Can we predict adherence to treatment in IBD patients?
- P562 Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
- P563 Psychotherapy experience and demand for it and their association in inflammatory bowel disease – results from an internet-based survey
- P564 Low-dose azathioprine improves long-term efficacy of infliximab maintenance treatment in Japanese patients with Crohn's disease
- P565 Assessments of clinical efficacy and mucosal healing in ulcerative colitis patients undergoing granulomonocytapheresis at different treatment frequencies
- P566 Frequency and type of drug-related side effects necessitating drug cessation in the Swiss inflammatory bowel disease cohort
- P567 Cross-sectional study of the low serum concentrations of testosterone in IBD and the influence on disease activity
- P568 Does infliximab therapy increase incidence of tuberculosis in patients with inflammatory bowel disease in an endemic area: a nationwide study from China
- P569 Sequential rescue treatments in steroid refractory ulcerative colitis: two-year follow-up
- P570 Current status of the effectiveness of infliximab in patients with ulcerative colitis
- P571 Can Crohn's colits be cured by surgery?
- P572 Medical therapies for stricturing Crohn's disease: efficacy and cross-sectional imaging predictors of therapeutic failure
- P573 Impact of the duration of combination therapy on clinical and pharmacological efficacy of infliximab in inflammatory bowel diseases
- P574 Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)
- P575 AZA-related toxicity isn't aggravated by concomitant drugs in IBD patients
- P576 Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's disease?
- P577 “Treat to target” recommendations in ulcerative colitis in practice: clinician perceptions and potential barriers
- P578 Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort study
- P579 Complete disease resolution after allogenic hematopoietic stem cell transplantation in children with very early onset inflammatory disease and no identified monogenic mutation
- P580 Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” study
- P581 Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients: a double-blind, randomized, placebo controlled trial
- P582 The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016
- P583 Trends in endoscopy management after surgery in a national cohort of Spanish Crohn's disease patients. Results from PRACTICROHN study
- P584 A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?
- P585 Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategy
- P586 A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experience
- P587 Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controls
- P588 Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54
- P589 Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis
- P590 Reasons for discontinuation and switch of biologic therapy in IBD: findings from a large international observational study (03)
- P591 Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach
- P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort
- P593 Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies
- P594 Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn's disease
- P595 The influence of vitamin D on expression of cytokines mRNA in IBD
- P596 FMT in patients with steroid dependant ulcerative colitis a single centre observational study
- P597 Ustekinumab use in Crohn's disease: a tertiary centre experience
- P598 Mucosal and transmural healing during anti-TNF therapy. Is fecal calprotectin a marker of therapeutic response?
- P599 Home testing for faecal calprotectin: follow-up results from the first UK trial
- P600 Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease
- P601 Can Amitriptylin improve the quality of life in patients with Crohn's disease?
- P602 Clinical/biochemical predictors of response to anti-TNFa therapies in a tertiary referral centre
- P603 Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohn's disease. Results from the PRACTICROHN study
- P604 Usefulness of stool hemoglobin and fecal calprotectin for detecting of mild to moderate ulcerative colitis
- P605 Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA
- P606 Intestinal fatty acid binding protein parallels temporal changes in Harvey-Bradshaw Index and TNFα in response to infliximab in Crohn's disease
- P607 Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989–2013): a multicenter nationwide study
- P608 New anti-migration extractible metal stents for Crohn's disease strictures: a nationwide GETAID-SFED cohort study
- P609 A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes
- P610 Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept study
- P611 Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy
- P612 Exclusive enteral nutrition in adults with active Crohn's disease is associated with decreased disease activity
- P613 Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-alpha inhibitors and conventional immunosuppressants
- P614 Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis
- P615 The unfinished symphony: golimumab is efficient in patients with refractory Crohn's disease
- P616 Natural history and phenotype of inflammatory bowel disease with co-existent celiac disease
- P617 Extraintestinal autoimmune phenomena during treatment with vedolizumab
- P618 Rapidity of onset of response to adalimumab in luminal Crohn's disease. Data from RAPIDA trial
- P619 Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experience
- P620 Network meta-analysis of efficacy and safety of different intravenous iron compounds for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease
- P621 Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study
- P622 Efficacy of probiotics in inflammatory bowel disease: systematic review and meta-analysis
- P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database
- P624 Chromoendoscopy and narrow band imaging versus conventional white light endoscopy for detection of neoplasia in ulcerative colitis – a systematic review and meta-analysis
- P625 Ustekinumab use in Crohn's disease: effectiveness of dose escalation
- P626 Ustekinumab for the treatment of perianal fistulas in patients with Crohn's disease
- P627 Surrogate markers of mucosal healing in Crohn's disease patients in clinical remission under biological/immunomodulator treatment
- P628 Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysis
- P629 Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year
- P630 The long-term efficacy of adalimumab on Crohn's disease comorbid with perianal lesions and poor prognostic factor analysis
- P631 Results and predictors of outcome of endoscopic balloon dilation of colonic strictures in inflammatory bowel diseases
- P632 Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's disease
- P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease
- P634 Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel disease
- P635 Enteral nutrition in the treatment of young adults with active Crohn's disease
- P636 Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's disease under anti-Tnf therapy
- P637 Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical response
- P638 Release of 5-aminosalicylic acid from mesalazine formulations: a novel dynamic dissolution model simulating gastrointestinal pH changes
- P639 Switching from originator-infliximab to biosimilar-Infliximab in IBD-patients does not lead to significant changes in infliximab trough levels
- P640 Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective study
- P641 Long-term outcome of adalimumab therapy and predictors of response in 254 patients with Crohn's disease: a hospital-based cohort study from Korea
- P642 Impact of histological and endoscopic remission in clinical recurrence and recurrence-free time in ulcerative colitis
- P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease
- P644 Factors and salvage surgery for treatment of pouch failure after restorative proctocolectomy for ulcerative colitis – a single-institution study
- P645 The introduction of infliximab therapeutic drug level monitoring for is associated with cost savings in a cohort of patients in a large district general hospital
- P646 Low FODMAPs diet as a magic bullet in reducing symptoms in different gastrointestinal diseases
- P647 Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series
- P648 The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD
- P649 Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?
- P650 The prognostic impact of radical resection margins on the Recurrence of Crohn's disease
- P651 Barriers to clinical research in children with inflammatory bowel disease: the patients' perspective
- P652 Unmet needs of physicians managing inflammatory bowel disease. A Survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)
- P653 The efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysis
- P654 Mucosal healing with a second anti-TNF-α in patients with ulcerative colitis after the failure of the previous anti-TNF-α treatment
- P655 A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel disease
- P656 Is there a role for additional oral mesalamine therapy in the treatment of ulcerative proctitis with skip inflammation?
- P657 The predictors and clinical outcomes of follow up loss of clinics in patients with inflammatory bowel disease
- P658 The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy and quality of life
- P659 Therapeutic drug monitoring of anti-TNFα drugs in a UK tertiary IBD unit
- P660 Prevalence and clinical course of cytomegalovirus colitis in Asian patients with acute exacerbation of ulcerative colitis
- P661 Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational
- P662 Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
- P663 Switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study
- P664 The transitioning healthcare economy of IBD: changes in resource allocation over time
- P665 Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective study
- P666 Short-term outcomes of adalimumab for patients with Crohn's disease and associated prognostic factors: a multicentre retrospective cohort study
- P667 Safety of anti-TNF treatment in liver transplant recipients – a meta-analysis
- P668 Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
- P669 Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registry
- P670 Evaluating the management of Vitamin D in Crohn's disease patients in a secondary care population
- P671 Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients
- P672 Surgical and anti-TNFs combined therapy prevents Crohn's perianal fistula recurrence: a systematic review and meta-analysis
- P673 Intra-abdominal collections in Crohn's disease: outcomes following anti-TNF therapy
- P674 Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in paediatric Crohn's disease patients
- P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis – 54 week data
- P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States
- P677 Impact of patient reported outcomes, coping strategies and psychosocial factors on medication adherence in inflammatory bowel disease
- P678 Did toxicity profile of azathioprine changed within the last 10 years: comparative 17 years data from a single tertiary IBD center
- P679 Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment
- P680 Quality of sex life in patients with inflammatory bowel disease: the gastroenterologists' perspective
- P681 Assessing internet based information used to aid patient decision making in surgery for perianal Crohn's fistula
- P682 Risk factors and clinical outcome in IBD patients with melanoma
- P683 Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF-α treatment
- P684 A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
- P685 Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease
- P686 Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitis
- P687 Fate of the rectum in anorectal Crohn's disease
